Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atea Pharmaceuticals, Inc.AVIR · Entity 5580 | Director | June 18, 2026 | June 23, 2026 |
| Celcuity Inc.CELC · Entity 3991 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atea Pharmaceuticals, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 121,745 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 29,600 · Balance 121,745 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 29,600 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The RSUs vested in full on June 18, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,700 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 26,700 · Balance 26,700 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2036-06-17 | Direct | 37,700 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 37,700 · Balance 37,700 F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The RSUs vested in full on June 18, 2026.
F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
Celcuity Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2035-05-19 | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Gift · Disposed 14,048 · Balance 0 F1: 100% vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2035-05-19 | IndirectBy Trust | 14,048 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Gift · Acquired 14,048 · Balance 14,048 F1: 100% vested. F2: The reporting person and her spouse are the trustees and beneficiaries. The reporting person continues to beneficially own these securities held by the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% vested.
F2: The reporting person and her spouse are the trustees and beneficiaries. The reporting person continues to beneficially own these securities held by the trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 37,700 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001193125-26-279718 · ownership.xml · derivative · entry 4 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,700 Underlying: Common Stock · 37,700 shares Expires 2036-06-17 F4 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279718 · ownership.xml · derivative · entry 3 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F3 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279718 · ownership.xml · derivative · entry 2 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in full on June 18, 2026. F2 · derivative.expiration_date: The RSUs vested in full on June 18, 2026. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279718 · ownership.xml · nonDerivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:18 UTC | Celcuity Inc. CELC · Entity 3991 | GiftStock Option (right to buy) · Derivative | 14,048 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001829248-26-000004 · form4-06122026_080606.xml · derivative · entry 2 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 14,048 Underlying: Common Stock · 14,048 shares Expires 2035-05-19 F1 · derivative.exercise_date: 100% vested. F2 · ownership.nature: The reporting person and her spouse are the trustees and beneficiaries. The reporting person continues to beneficially own these securities held by the trust. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:18 UTC | Celcuity Inc. CELC · Entity 3991 | GiftStock Option (right to buy) · Derivative | 14,048 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001829248-26-000004 · form4-06122026_080606.xml · derivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,048 shares Expires 2035-05-19 F1 · derivative.exercise_date: 100% vested. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 22:25 UTC | Celcuity Inc. CELC · Entity 3991 | GrantCommon Stock | 1,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001829248-26-000002 · form4-06092026_100617.xml · nonDerivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,530 F1 · shares: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027. Read SEC document |
| May 18, 2026 Filed May 21, 2026 22:30 UTC Amendment | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | PurchaseCommon Stock | 6,100 | $4.17 | $25,446.15 |
DisclosureSEC source: 0001193125-26-235039 · ownership.xml · nonDerivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,145 F1 · date: This Form 4/A has been filed solely to correct the date of the transaction reported in Column 2 of Table I of the Reporting Person's Form 4 filed on May 20, 2026, which was inadvertently noted as "May 18, 2025" instead of "May 18, 2026." F2 · price: The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089607 · ownership.xml · derivative · entry 4 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units were fully vested as of June 20, 2025 F4 · derivative.expiration_date: The restricted stock units were fully vested as of June 20, 2025 Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0000950170-25-089607 · ownership.xml · derivative · entry 3 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2035-06-19 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089607 · ownership.xml · derivative · entry 2 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089607 · ownership.xml · nonDerivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:21 UTC | Celcuity Inc. CELC · Entity 3991 | GiftStock Option (right to buy) · Derivative | 8,153 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 6 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 8,153 Underlying: Common Stock · 8,153 shares Expires 2034-06-04 F1 · derivative.exercise_date: 100% vested. F2 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:21 UTC | Celcuity Inc. CELC · Entity 3991 | GiftStock Option (right to buy) · Derivative | 8,153 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 5 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,153 shares Expires 2034-06-04 F1 · derivative.exercise_date: 100% vested. Read SEC document |
| May 19, 2025 Filed May 21, 2025 20:42 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 14,048 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001415889-25-013945 · form4-05212025_080522.xml · derivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,048 Underlying: Common Stock · 14,048 shares Expires 2035-05-19 F1 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2026, or if earlier, the date of the Company's 2026 Annual Meeting of Stockholders. Read SEC document |
| May 18, 2025 Filed May 20, 2026 20:15 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | PurchaseCommon Stock | 6,100 | $4.17 | $25,446.15 |
DisclosureSEC source: 0001193125-26-232612 · ownership.xml · nonDerivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,145 F1 · price: The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 24, 2024 Filed May 29, 2025 20:21 UTC | Celcuity Inc. CELC · Entity 3991 | GiftStock Option (right to buy) · Derivative | 11,645 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 4 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 11,645 Underlying: Common Stock · 11,645 shares Expires 2033-05-15 F1 · derivative.exercise_date: 100% vested. F2 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust. Read SEC document |
| June 24, 2024 Filed May 29, 2025 20:21 UTC | Celcuity Inc. CELC · Entity 3991 | GiftStock Option (right to buy) · Derivative | 11,645 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 3 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,645 shares Expires 2033-05-15 F1 · derivative.exercise_date: 100% vested. Read SEC document |
| June 24, 2024 Filed May 29, 2025 20:21 UTC | Celcuity Inc. CELC · Entity 3991 | GiftStock Option (right to buy) · Derivative | 16,300 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 2 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2032-09-12 F1 · derivative.exercise_date: 100% vested. F2 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust. Read SEC document |
| June 24, 2024 Filed May 29, 2025 20:21 UTC | Celcuity Inc. CELC · Entity 3991 | GiftStock Option (right to buy) · Derivative | 16,300 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2032-09-12 F1 · derivative.exercise_date: 100% vested. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 21:54 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0000950170-24-076363 · ownership.xml · derivative · entry 2 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2034-06-20 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 21:54 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076363 · ownership.xml · derivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074989 · ownership.xml · derivative · entry 2 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock unites are fully vested. F3 · derivative.expiration_date: The restricted stock units do not have an expiration date. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074989 · ownership.xml · nonDerivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:16 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 8,153 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001062993-24-012032 · form4.xml · derivative · entry 5 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,153 Underlying: Common Stock · 8,153 shares Expires 2034-06-04 F3 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2025, or if earlier, the date of the Company's 2025 Annual Meeting of Stockholders. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 46,750 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0000899243-23-016129 · doc4.xml · derivative · entry 2 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,750 Underlying: Common Stock · 46,750 shares Expires 2033-06-15 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 16, 2023, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-016129 · doc4.xml · derivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,150 Underlying: Common Stock · 33,150 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:26 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 11,645 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001062993-23-011389 · form4.xml · derivative · entry 4 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,645 Underlying: Common Stock · 11,645 shares Expires 2033-05-15 F3 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2024, or if earlier, the date of the Company's 2024 Annual Meeting of Stockholders. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:10 UTC | Celcuity Inc. CELC · Entity 3991 | PurchaseCommon Stock | 5,000 | $9.68 | $48,383.00 |
DisclosureSEC source: 0001062993-22-022722 · form4.xml · nonDerivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.6500 to $9.7000 inclusive. The reporting person undertakes to provide Celcuity Inc., any security holder of Celcuity Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 20:06 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 16,300 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001437749-22-022425 · rdgdoc.xml · derivative · entry 2 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2032-09-12 F2 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2023, or if earlier, the date of the Company's 2023 Annual Meeting of Stockholders. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 20:06 UTC | Celcuity Inc. CELC · Entity 3991 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001437749-22-022425 · rdgdoc.xml · derivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-09-12 F1 · derivative.exercise_date: 2,500 shares vest on each of 9/12/23, 9/12/24, 9/12/25 and 9/12/26. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 23:47 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 61,264 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0000899243-22-023501 · doc4.xml · derivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,264 Underlying: Common Stock · 61,264 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) equal monthly installments following June 17, 2022, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 02:41 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | PurchaseCommon Stock | 12,000 | $8.57 | $102,795.60 |
DisclosureSEC source: 0000899243-21-049313 · doc4.xml · nonDerivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,295 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.66, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 21:30 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 34,025 | $0.00 Strike: $23.39 | $0.00 |
DisclosureSEC source: 0000899243-21-025037 · doc4.xml · derivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,025 Underlying: Common Stock · 34,025 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) equal monthly installments following June 18, 2021, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:09 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionSeries D-1 Convertible Preferred Stock · Derivative | 4,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030332 · doc4.xml · derivative · entry 3 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Marc & Polly Murphy Revocable Family Trust dated March 13, 2002 Disclosed balance after: 0 Underlying: Common Stock · 4,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:09 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionSeries D Convertible Preferred Stock · Derivative | 7,122 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030332 · doc4.xml · derivative · entry 2 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Marc & Polly Murphy Revocable Family Trust dated March 13, 2002 Disclosed balance after: 0 Underlying: Common Stock · 7,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:09 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionCommon Stock | 11,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030332 · doc4.xml · nonDerivative · entry 1 Murphy Polly A. · CIK 0001829248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Marc & Polly Murphy Revocable Family Trust dated March 13, 2002 Disclosed balance after: 11,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.